This press release contains forward - looking statements, including expectations regarding adjudication of MACE events, results and related timing and announcements with respect to Amarin's REDUCE - IT cardiovascular outcomes study; expectations related to the final outcomes of the REDUCE - IT study and the
anticipated successful completion of the REDUCE - IT study; and statements regarding the potential and
therapeutic benefits of Vascepa.